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CADM1 is a TWIST1-regulated suppressor
of invasion and survival
Edward J. Hartsough1,2,3, Michele B. Weiss1, Shea A. Heilman1, Timothy J. Purwin1, Curtis H. Kugel III1,
Sheera R. Rosenbaum1, Dan A. Erkes1, Manoela Tiago1, Kim HooKim4, Inna Chervoneva2,5 and Andrew E. Aplin1,2
Abstract
Metastatic cancer remains a clinical challenge; however, patients diagnosed prior to metastatic dissemination have a
good prognosis. The transcription factor, TWIST1 has been implicated in enhancing the migration and invasion steps
within the metastatic cascade, but the range of TWIST1-regulated targets is poorly described. In this study, we
performed expression proﬁling to identify the TWIST1-regulated transcriptome of melanoma cells. Gene ontology
pathway analysis revealed that TWIST1 and epithelial to mesenchymal transition (EMT) were inversely correlated with
levels of cell adhesion molecule 1 (CADM1). Chromatin immunoprecipitation (ChIP) studies and promoter assays
demonstrated that TWIST1 physically interacts with the CADM1 promoter, suggesting TWIST1 directly represses
CADM1 levels. Increased expression of CADM1 resulted in signiﬁcant inhibition of motility and invasiveness of
melanoma cells. In addition, elevated CADM1 elicited caspase-independent cell death in non-adherent conditions.
Expression array analysis suggests that CADM1 directed non-adherent cell death is associated with loss of
mitochondrial membrane potential and subsequent failure of oxidative phosphorylation pathways. Importantly, tissue
microarray analysis and clinical data from TCGA indicate that CADM1 expression is inversely associated with melanoma
progression and positively correlated with better overall survival in patients. Together, these data suggest that CADM1
exerts tumor suppressive functions in melanoma by reducing invasive potential and may be considered a biomarker
for favorable prognosis.
Introduction
Patients presenting with early stage cancers who
undergo surgical intervention have a favorable overall
survival. By contrast the prognosis for patients with
metastatic disease is poor. Metastatic progression is a
complex process that includes the ability to migrate and
invade through the in situ organ, intravasate into vascu-
lature, resist anoikis to survive in the bloodstream, and
extravasate for colonization of a distant organ1. Asso-
ciated with the initial migration and invasion, tumor cells
need to alter a gene expression program, collectively
referred to as epithelial-mesenchymal transition (EMT)2.
TWIST1 is a transcription factor implicated in both
developmental and pathological EMT3,4. TWIST1 con-
tributes to an EMT-like phenotype switch in melanoma
that enhances migratory and invasive function5,6. Our
group has previously demonstrated that TWIST1 plays a
role in the ability of melanoma cells to invade through the
dermal layer in part by up-regulating the matrix metal-
loprotease, MMP-17. However, the range of TWIST1
targets is poorly characterized.
Dysregulation of cell-cell junctions is an important
aspect of pathological EMT8, and TWIST1 have been
demonstrated to contribute to this process2,8. The cell
adhesion molecule (CADM) family contains four proteins
in the immunoglobulin containing super family that are
associated with cell-cell junctions9. The four members of
the CADM family all share three extracellular
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immunoglobulin (Ig) repeats as well as a single trans-
membrane domain and a short cytosolic region on the C-
terminus10. In addition to cell-cell junctions, CADMs are
known to play a role in neurobiology11–13 and sperma-
togenesis14. CADM family members are generally regar-
ded as tumor suppressors. For instance, CADM4 has been
shown to suppress colon cancer tumorigenicity15, and
CADM2 may play a tumor suppressive role in prostate
cancer as epigenetic silencing and deletion of the CADM2
locus has been frequently observed16,17. Similarly,
CADM1 (also known as TSLC1, NECL-2, IGSF4, Syn-
CAM1) serves as a tumor suppressor in a variety of
human cancers including lung18,19, nasopharyngeal car-
cinoma20, among others (reviewed in21). CADM mole-
cules function via either homophilic or heterophilic
dimerization22. These interactions link to the actin
cytoskeleton through recruitment of DAL-1/4.1B actin
binding proteins as well as membrane-associated guany-
late kinases (MAGuKs) as scaffolds23–25. Thus, CADM
family proteins may be involved in cell-cell adherence and
potentially play a role in EMT-like processes and meta-
static progression.
Using melanoma as a model system, we demonstrate
that CADM1 is a critical negative regulator of metastatic
traits. CADM1 was found to be repressed by the tran-
scription factor TWIST1. This repression persisted across
multiple melanoma cell lines of different genetic back-
grounds. We found that CADM1 expression in melanoma
reduces migratory and invasive potential and potently
induces cell death in non-adherent cells. Furthermore,
high CADM1 expression in patient samples was linked to
less aggressive melanomas and associated with improved
progression free and overall survival. These ﬁndings
highlight CADM1 as a possible prognostic marker.
Results
TWIST1 regulates expression of EMT and cell adhesion
molecule pathways
TWIST1 promotes EMT and metastatic-traits, but the
repertoire of TWIST1 targets is not well understood3–7.
We explored the TWIST1-regulated transcriptome
through expression array analysis using invasive mutant
BRAF melanoma cells as a model. Vertical growth phase
(VGP) WM793TR cells expressing control shRNA,
TWIST1 shRNA, or TWIST1 shRNA and a CMV-
regulated TWIST1 rescue construct were assayed
(Fig. 1a). Median-centered log2 expression values were
represented via heatmap (Fig. 1b). Samples were ordered
by optimal leaf ordering and a probability curve of each
gene’s correlation to TWIST1 expression is provided
(Fig. 1b left). Using geneset enrichment analysis (GSEA) to
query mSigDB’s Hallmark Pathways, the highest scoring
TWIST1-regulated pathway was Epithelial Mesenchymal
Transition (EMT) (Fig. 1c). The most strongly correlated
genes in the EMT pathway were further analyzed. Genes
from the EMT hallmark pathway with an absolute Pearson
correlation value of >0.9 were listed with the associated r-
value and heatmap representation of expression (Fig. 1d).
Taken together, these results suggest that TWIST1 reg-
ulates EMT pathway-related genes in melanoma.
CADM1 is negatively regulated by TWIST1
Analysis of the most highly regulated TWIST1 targets
directed us to further investigate CADM1, due to its
potential role as a tumor suppressor21. Microarray ﬁndings
were validated by qRT-PCR, conﬁrming that CADM1 is
inversely associated with TWIST1 transcript level (Fig. 2a).
CADM1 transcript and protein levels were increased after
siRNA mediated knockdown of TWIST1 with multiple
independent siRNAs (Fig. 2b, c). It is noteworthy that
treatment with TWIST1 siRNA #2 caused a shift in the
molecular weight of CADM1, an effect that may warrant
further exploration. The inverse relationship of TWIST1
and CADM1 was consistent across cell lines regardless of
mutant BRAF or NRAS genotype (Fig. 2d). Furthermore,
inducible TWIST1 expression reduced CADM1 transcript
levels (Fig. 2e), CADM1 promoter directed reporter
activity (Fig. 2f), and suppressed CADM1 protein levels
(Fig. 2g). TWIST1 has been reported to act as a tran-
scriptional repressor for a number of genes including E-
cadherin, ERα, and Sox926–28. Five E-boxes, a well-deﬁned
TWIST1 binding motif, were identiﬁed in the ~ 1400 base
pair CADM1 proximal promoter region3,29 (Supplemen-
tary Fig. 1). This prompted us to investigate whether
TWIST1 physically interacts with the E-boxes in CADM1
promoter via chromatin immunoprecipitation (ChIP).
ChIP of genomic extracts of WM793 cells demonstrated
an enriched presence of TWIST1 at the CADM1 promoter
region containing E-box #3 and #4 (Fig. 2h). These data
support the notion that TWIST1 is directly acting to
repress CADM1 expression.
Expression of CADM1 is inversely related to ERK1/
2 signaling
Since TWIST1 levels are modulated by ERK1/2 signal-
ing7, we tested the effects of ERK1/2 pathway inhibition
on CADM1 expression. Western blot analysis of WM793
cells treated with the selective mutant BRAF inhibitor,
PLX4720, (the tool-compound for vemurafenib30)
revealed an increase of CADM1 associated with reduced
phospho-ERK1/2 and TWIST1 levels (Fig. 3a). This
response was consistent in all cell lines tested (Fig. 3b).
CADM1 promoter activity was also increased after
treatment with PLX4720 (Fig. 3c). Furthermore, this
relationship was assayed in PLX4720-resistant cell lines31.
Resistant cells treated with PLX4720 displayed a weak
upregulation of CADM1 expression compared to parental
cells (Supplementary Fig. 2A). To address if the link
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between CADM1 levels and ERK1/2 signaling is present
in non-transformed melanocytes, we utilized the immor-
talized mouse melanocyte cell line, melan-a32. CADM1
levels in melan-a cells increased with suppression of
phospho-ERK1/2. Additionally, CADM1 was decreased
with inducible BRAF V600E expression, an effect that was
reversed following BRAF-MEK pathway inhibition
(Fig. 3d). RAF inhibitor alone had little effect possibly due
to poor suppression of ERK1/2 signaling after mutant
BRAF overexpression. In mutant BRAF melanoma cells,
ﬂow cytometry revealed that PLX4720 induced an
increase of surface exposed CADM1 (Fig. 3e and Sup-
plementary Fig. 2B). Taken together, these results suggest
ERK1/2 inhibition is associated with reduction of
TWIST1 and an increase of CADM1 levels.
CADM1 expression reduces melanoma cell invasion and
migration
Since CADM1 is a cell adhesion protein, we tested if
CADM1 could affect invasion and migration7,33–37. Human
melanoma cell lines were transduced to inducibly express
CADM1 or CADM1 shRNA constructs (Fig. 4a). In
matrigel-coated Boyden chambers, CADM1 overexpression
suppressed the invasiveness of melanoma cells, while
CADM1 knockdown increased melanoma cell invasion
(Fig. 4b). Similarly, in serum-directed migration assays,
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Fig. 1 Microarray analysis of TWIST1 regulated genes. a Western blot analysis of WM793TR cells utilized in microarray analysis. b A heat map
displaying median-centered log2 expression levels for each sample with the data on a correlation value interval scale. Above the sample numbers is a
dendrogram plot displaying log-transformed linkage distances with samples arranged in optimal leaf order. Clusters are based on expression values
for the top 250 genes positively or negatively correlating with TWIST1. A line plot showing kernel smoothing of probability density function estimates
for gene correlation values is on the left, followed by the correlation value range. Sample conditions are displayed by different shades of green.
c GSEA results showing statistically signiﬁcant (BH FDR < 0.05) Hallmark gene sets. Normalized enrichment score (NES) values for each gene set are
represented by the height of the bars. The color scale represents correlation values ranging from −1 to 1 with a color gradient interval rate of 0.1.
Gene set NES bars are colored based on the fraction of enriched genes having a correlation value within a given range. The width of the bars
represents the signiﬁcance cutoff level, with FDR < 0.001, 0.01, 0.05 ranging from largest to smallest, respectively. d A heat map containing the EMT
hallmark gene set genes (n= 20) with an absolute Pearson correlation value > 0.9. Genes are sorted based on hierarchical clustering. Pearson
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CADM1 overexpression reduced cell migration, while
knockdown enhanced this process (Fig. 4c). Exogenous
expression CADM1 elicited similar responses in
WM793TR cells (Supplementary Figs. 3A-3B) and had a
suppressive effect on 2D wound closure (Supplementary
Fig. 3c). We further explored the effect of CADM1
expression on melanoma invasiveness by utilizing collagen-
embedded 3D spheroid assays that models dermal out-
growth. Melanoma spheroids expressing CADM1 invaded
signiﬁcantly less than LacZ-expressing counterparts
(Fig. 4d, e). These assays were expanded to a 3D human
skin reconstruct model. Compared to LacZ expressing cells,
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CADM1 expression in 1205LuTR suppressed the invasive
depth of the melanoma (Fig. 4f). CADM1 is also known to
play a role in cell-cell junctions38, therefore, we visualized
CADM1 localization and cell morphology. A375TR cells
expressing CADM1 showed strong CADM1 localization to
cell-cell boundaries and induced a cobblestone-like cell
morphology (Supplementary Fig. 3D). Next, we tested the
effect of BRAF inhibition on CADM1 localization. CADM1
was localized at the cell boundaries following PLX4720
treatment (Supplementary Fig. 3E). Additionally, both
CADM1 expression and PLX4720 treatment resulted in
cellular aggregation (Supplementary Figs. 3F and 3G).
Together, these data demonstrate that CADM1 suppresses
migratory and invasive potential, as well as induces cell
adhesion and aggregation in human melanoma cells.
CADM1 induces cell death in non-adherent conditions
We next analyzed a role for CADM1 in resistance to
anoikis is a key step to metastatic colonization of distant
sites. Flow cytometry analysis of annexin V/propidium
iodine staining indicated that while expression of
CADM1 had either no to minor effects in adherent
conditions (Fig. 5a), expression of CADM1 in non-
adherent conditions strongly induced cell death (Fig. 5b).
Levels of exogenous CADM1 were equivalent in adherent
and non-adherent conditions within each cell line (Sup-
plementary Fig. 4A). These effects were not general
effects since expression of exogenous ErbB3, an alter-
native transmembrane protein, did not induce anoikis
(Supplementary Figs. 4B, 4C). CADM1-induced cell
death in non-adherent conditions was partially rescued
when matrigel was added to cells in suspension, sug-
gesting that the cell death effect of CADM1 is suppressed
when cells are associated with extracellular matrix
(Fig. 5c). It is noteworthy that while matrigel partially
rescued the effects of CADM1 expression in suspension,
the pan-caspase inhibitor, Z-VAD FMK, did not (Sup-
plementary Figs. 4D-4F). Furthermore, while no changes
in viability were observed for CADM1-expressing cells in
2D MTT assays, CADM1 expressing cells formed fewer
and smaller colonies in soft agar growth assays (Supple-
mentary Fig. 4G and Fig. 5d). Together these data
implicate CADM1 as a suppressor of melanoma cell
viability in non-adherent conditions.
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melanoma cell invasiveness was assayed in 3D skin reconstruct model. The depth of melanoma was measured from at least 70 measurements across
two experiments. * represents p < 0.05 as determined by t-test, error bars are ±SEM. Scale bar= 200 μM
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CADM1 expression in non-adherent conditions is
associated with mitochondrial membrane depolarization
and a parthanatos-like phenotype
CADM1 associated non-adherent cell death was not
driven through caspase activity (Supplementary Fig. 4D-F),
and was not a result of altered FAK, AKT, or BCL-2 family
members (Supplementary Fig. 5A-B). Consequently, we
performed microarray analysis to elucidate the differential
roles of CADM1 in melanoma cells in adherent vs. non-
adherent conditions. GSVA analysis identiﬁed three
pathways (oxidative phosphorylation, myc targets V2, and
apical surface) in the MSigDB Hallmark dataset associated
with CADM1 expression in suspended cells (Fig. 6a).
These three pathways have an interaction statistic of less
than 0.25; an appropriate threshold indicated by GSEA for
identiﬁcation of target pathways. CADM1 expression and
GSVA score of each of the twelve samples used in the
study are shown (Fig. 6b). These three pathways demon-
strated consistent GSVA scoring except for reduced scores
when CADM1 is expressed in suspension.
We focused on oxidative phosphorylation since it has
been linked to adhesion-related effects on cell survival in
breast cancer39 and CADM1 plays a role in mitochondrial
biology in human lung papillary adenocarcinoma40. We
tested CADM1 effects on mitochondrial dysfunction by
staining cells with Mitotracker GreenFM and CMXRos
(stains for total mitochondria and mitochondrial mem-
brane potential, respectively) followed by ﬂow cytometry
analysis. We observed a signiﬁcant reduction in CMXRos
staining, indicating poorly polarized mitochondrial
membranes when CADM1-expressing cells were sub-
jected to non-adherent conditions (Fig. 6c). Similar to the
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annexin V/propidium iodine based experiments, this
reduction in membrane potential was associated with a
signiﬁcant decrease of living cells, as indicated by a mul-
tiplexed Zombie stain (Fig. 6d).
To identify how CADM1 expression in non-adherent
conditions elicits cell death, we investigated mechanisms
which coupled mitochondrial membrane depolarization
with caspase-independent cell death. Hyperactivated poly
(ADP-ribose) polymerase 1 (PARP1) plays a role in mito-
chondrial membrane depolarization and has been impli-
cated as a mediator of caspase-independent cell death41–43.
Western blotting demonstrated increased levels of poly
ADP-ribose when CADM1 was expressed in non-adherent
conditions (Fig. 6e). We then measured cell viability via
propidium iodine staining in cells treated with or without
the PARP inhibitor talazoparib (PARPi) in both adherent
and non-adherent conditions. PARPi or CADM1 expres-
sion did not affect propidium iodine staining of adhered
cells; although PARPi elicited a modest increase in cell
death of LacZ-expressing cells in suspension (Fig. 6f).
Interestingly, PARPi treatment rescued ~ 50% of the
CADM1-induced non-adherent cell death (Fig. 6f). Similar
results were obtained with a second PARPi, olaparib (Sup-
plementary Fig. 5B). Taken together, these data suggest that
CADM1 expression in non-adherent conditions leads to
mitochondrial membrane depolarization and cell death, at
least in part, via a mechanism involving PARP1.
CADM1 is reduced in melanoma progression and is
correlated with overall survival
Since CADM1 reduced migration and invasion, and
elicited an anoikis-like phenotype in non-adherent con-
ditions, we hypothesized that CADM1 would be expres-
sed at lower levels in more aggressive tumors. A human
melanoma panel containing radial growth phase, vertical
growth phase (VGP), and metastatic cell lines were
assayed for CADM1 expression (Fig. 7a). Western blotting
revealed CADM1 levels were lowest in cell lines with
more aggressive behavior. Similar results were obtained
when we expanded these studies to a human melanoma
tissue microarray. Immunohistochemical staining sug-
gested that CADM1 decreases from nevi to melanoma
in situ to metastatic melanoma (Fig. 7b). We next ques-
tioned whether CADM1 expression was associated with a
better prognosis in melanoma patients. We utilized the
publicly available SKCM TCGA dataset to analyze
CADM1 expression as an indicator of overall survival
(OS) and progression free survival (PFS). In univariate
survival analysis, log-transformed CADM1 transcript
levels were found to be a signiﬁcant predictor of OS, with
higher levels of CADM1 associated with longer survival
(hazard ratio (HR) is 0.87, 95% CI: 0.77, 0.98; p= 0.027).
Similarly, patients with higher levels of CADM1 are
associated with longer progression-free survival
(HR= 0.68 (95% CI: 0.49, 0.94; p= 0.019)). Kaplan–Meier
curve estimates of OS in 248 patients with low CADM1
expression (CADM1 ≤ 1960) vs. 68 patients with high
CADM1 expression (CADM1 > 1960) show a signiﬁcant
increase in overall survival for CADM1 high patients
(Fig. 7c). Additionally, a parsimonious Cox model
demonstrates CADM1 is a signiﬁcant predictor of OS and
is borderline signiﬁcant (p= 0.061) predictor of PFS
(Supplementary Figs. 6A and 6B). The HR for PFS (HR=
0.71, 95% CI: 0.50, 1.02) is more profound than the HR=
0.75 for the CADM1 effect on OS, however the p= 0.061
is likely the result of limited number of events16 in 95
patients available for PFS analysis. Together, these data
demonstrate that CADM1 levels are decreased as mela-
noma progresses and high levels of CADM1 are asso-
ciated with better clinical outcomes.
Discussion
TWIST1 is a prototypical transcription factor involved
in EMT44, is overexpressed in many tumor types includ-
ing melanoma45,46, and enhances invasion of melanoma
cells through the dermal layer7. In this study, expression
array analysis was used to provide novel insights into the
TWIST1-regulated transcriptome. We found TWIST1
has a strong (Pearson correlation > 0.9) inverse correlation
with the expression pattern of cell adhesion molecule 1
(see ﬁgure on previous page)
Fig. 6 CADM1 expression in non-adherent conditions is associated with dysfunctional mitochondria and a parthanatos-like phenotype.
a Heat map showing the median-centered log2 average CADM1 (top row) gene expression and MSigDB’s Hallmark gene set GSVA scores for each of
the 2 condition factor groups (n= 3) (left panel). Gene sets were sorted based on hierarchical clustering of GSVA scores. Bar plot of the negative
log10 transformed BH adjusted p-value for each gene set (right panel). The top 3 gene sets (all with BH adjusted p-values < 0.25) are arbitrarily
colored while the rest are in gray. The red, dotted line represents BH adjusted p-value of 0.25. b Line plot of median-centered log2 CADM1 expression
(red) and GSVA score values for CADM1 or LacZ expressing cell lines, plated or in suspension samples (n= 12) for the top 3 gene sets: Oxidative
Phosphorylation (purple), MYC Targets v2 (green), and Apical Surface (blue). Colors correspond to those shown in part (a). c Representative stacked
histogram and quantiﬁed average mean ﬂuorescence intensity (MFI) of CMXRos stained LacZ or CADM1 expressing WM793TR cells in adherent or
suspension conditions. * represents p < 0.05 as determined by 2-tailed t-test assuming unequal variance, and error bars are ±SEM. d Representative
stacked histogram of Zombie staining and percent living cells as measured by absence of Zombie staining were quantiﬁed. Error bars and statistics
are similar to (c). e Western blot analysis of poly ADP-Ribose (PAR) levels in whole cell extracts of LacZ or CADM1 expressing WM793TR cells cultured
in the indicated conditions. f Representative stacked histograms of propidium iodine staining and quantiﬁed percentage of propidium iodine
negative WM793TR LacZ and CADM1 cells in adhered and suspension conditions. Cells were treated with or without 5 μM talazoparib (PARPi)
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(CADM1). CADM1 was inversely associated with
TWIST1 across melanoma genotypes and TWIST1
occupied the proximal CADM1 promoter. We showed
that CADM1 suppresses invasive and migratory potential
of melanoma cells, and potently induces cell death when
melanoma cells are cultured in non-adherent conditions.
Our results are likely impactful since TCGA analysis
suggests patients with high CADM1-expressing tumors
have better OS. Our data support that CADM1 is acting
as a suppressor of metastatic-like traits in melanoma cells
and that CADM1 expression is correlated with an
increase of OS in melanoma patients.
The aggressiveness of melanoma is thought to be a
result of gene expression alterations creating a condition
of enhanced self-renewal and motility that is unresponsive
to differentiation cues47. The tumor microenvironment
and cell-cell interactions play a key role in tumor pro-
gression. As an adhesion molecule, CADM1 may be
contributing to cellular junctions which propagate pro-
liferative, motility, or differentiation signals. Interestingly,
CADM1 has been implicated in the biology of de-
differentiated cells. CADM1 expression reduced the
oncogenic potential of hepatic cancer stem cells48 and
inhibited the proliferation, migration, and wound healing
abilities of the stem-cell like hair follicle bulge keratino-
cytes49. Our cell line panel and tissue microarray analysis
may support these ﬁndings as CADM1 expression
decreases in more aggressive cells. While the function of
CADM1 in the formation of nevi is unknown, our data
suggest CADM1 plays multiple tumor suppressive func-
tions that would likely be selected against as nevi clonally
evolve to in situ and metastatic disease.
We linked CADM1 expression to ERK1/2 activity.
Speciﬁcally, when cells were treated with inhibitors to
suppress phosphoERK1/2 levels, TWIST1 levels were
also decreased and CADM1 increased. Thus, CADM1
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may represent a new target of RAS-RAF-MEK-ERK1/2
pathway inhibition in metastatic melanoma patients.
Augmented CADM1 expression signiﬁcantly increased
cell death in non-adherent conditions, and reduced the
invasive and migratory potential of melanoma cells.
These data suggest that the increase of CADM1
resulting from treatment with BRAF and MEK inhibi-
tors may suppress the ability of tumor cells to intrava-
sate safely into the bloodstream and may, at least in part,
underlie the observation that patients on ERK1/2
pathway suppression treatment have less circulating
tumor cells50. In addition, a recent phase 2 trial found
that Stage III melanoma patients treated with BRAFi/
MEKi as a neoadjuvant prior to surgery and as adjuvant
after surgery, had a signiﬁcantly improved event-free
survival compared to standard of care51. Perhaps
CADM1 upregulation resulting from RAF-MEK-ERK
pathway inhibitors is contributing to the favorable
outcomes in this trial.
We found that CADM1 expression in non-adherent
conditions leads to cell death. This observation may
highlight a role for CADM1 in metastatic progression by
acting as a mediator of for anoikis resistance. Notably,
endogenous levels of CADM1 were reduced when mela-
noma cell lines were cultured in non-adherent conditions
(Supplementary Figs. 4A-4B). This response may repre-
sent a survival mechanism employed by circulating tumor
cells. Interestingly, CADM1-induced non-adherent cell
death was apparently not driven through caspase-driven
pathways. We found that when CADM1 is expressed in
non-adherent conditions, cell death was associated with
decreases in mitochondrial membrane potential and an
increase of poly-ADP ribose staining. Caspase-
independent cell death resulting from increased PARP
activity is termed parthanatos52,53 and was recently
implicated in melanoma resistance to targeted inhibi-
tors54. Given the high mutational load of melanoma,
PARP inhibitors (PARPi) were thought to represent an
efﬁcacious treatment avenue; however, clinical trials with
PARPi in melanoma patients have yielded poor results55.
Consistent with the potential susceptibility to CADM1-
induced non-adherent cell death, PARPi treatment pro-
duces differential effects on circulating tumor cells and a
PARPi clinical trial of castration-resistant prostate cancer
found a subset of patients with increased levels of circu-
lating tumor cells after treatment56. Our present study
indicating PARPi suppression of CADM1-induced non-
adherent cell death provides a rationale for these clinical
ﬁndings and could be a factor in PARPi efﬁcacy.
The work presented here demonstrates a previously
unknown function of TWIST1 in the metastatic pro-
gression of human melanoma. We found that TWIST1
acts to repress CADM1 levels and suppression of CADM1
appears to enhance traits needed for metastatic
dissemination of melanoma. In melanoma disease pro-
gression, CADM1 may act as a barrier to metastasis by
inhibiting the invasiveness, motility, and inducing cell
death in non-adherent conditions. While further studies
are needed to address the role of CADM1 in early steps of
melanomagenesis, CADM1 expression in late stage dis-
ease may correlate with prognosis.
Methods
Cell culture
WM793, 1205Lu, WM1366, and Scbl2 cells (all donated
by Dr. Meenhard Herlyn, Wistar Institute, Philadelphia,
PA in 2005) were cultured in 37 °C humidiﬁed chamber
with 5% CO2 in MCDB 153 media containing 20%
Leibovitz-L15 media, 2% fetal bovine serum, 0.2% sodium
bicarbonate, and 5 μg/mL insulin. A375 cells (purchased
from ATCC in 2005) were grown in DMEM with 10%
FBS. M229 and M238 (donated by Dr. Antoni Ribas in
2010) cells were grown in RPMI+ 10% FBS with 1%
L-glutamine. Melan-a cells (donated by Dr. Dorothy
Bennett in 2010) were grown in RPMI 1640 with 10% FBS,
1% L-glutamine, and 200 nM TPA. All media have 1%
penicillin/streptomycin. Cells are routinely assayed for
mycoplasma contamination with MycoScope kit
(Genlantis, San Diego, CA). Cells were most recently
assayed May of 2018. Cell line authentication via STR
analysis was completed in April 2018 for WM793 and
1205Lu cell lines. A375 and WM1366 cells were con-
ﬁrmed by STR analysis in April and May of 2015. STR
analysis for M238 and M229 cells was performed in April
2015 and November 2015, respectively, producing unique
proﬁles, while all other cells matched known proﬁles.
Chromatin immunoprecipitation
ChIP was performed as previously described7. Brieﬂy
WM793 lysates were sonicated, precleared with protein
A/G agarose beads, then incubated with Protein G
Dynabeads (Invitrogen) with either TWIST1 (Santa Cruz
Biotechnology) or anti-V5 epitope antibodies (Invitrogen).
Experiment was repeated four times. Primer pair
sequences were: β-actin F: AGTGTGGTCCTGCGACT
TCTAAG, R: CCTGGGCTTGAGAGGTAGAGTGT, CA
DM1 E-Box #1 F: TCCAGCGCATGTCATTAG, R: CC
TGTGGGGATCAGTGC, CADM1 E-Box #2 F: GATCT
ATTCCTTCGGTGCAAGG, R: CGGGTCTAGCTTCT
TGTACACC, CADM1 E-Box #3/4 F: AGAGACAGG
GGAAGCTCG, R: TTAGTCAAGGCTTCAGGTGAAG
AGC, CADM1 E-Box #5 F: GTCGGCAGGATTGCTTA
TTTC, R: GCTTTCTTTTCAGCCAGGC.
Statistics
Unless speciﬁed, all experiments were independently
performed three times. Error bars represent+ /− SEM.
Signiﬁcance was determined using a 2-tailed student’s
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T-test assuming unequal variance. p ≤ 0.05 was con-
sidered signiﬁcant and represented with a *. For the GSVA
analysis of the CADM1 microarray dataset, the interac-
tion statistic is deﬁned by a change that cannot be
explained by 2D vs. suspension alone, or by LacZ vs.
CADM1 expression alone, rather the interaction of both
of these conditions are considered simultaneously for
analysis.
Annexin V/Propidium iodine staining
2 × 105 (adherent) or 3 × 105 (non-adherent) cells were
seeded on 6-well dishes without or with a pre-coat of
Bacto agar. The next day, doxycycline was added at 100
ng/mL to induce transgene or shRNA expression. After
24 h, cells were harvested an incubated with 5 uL of
Annexin V-APC (BD Biosciences) and 0.2 mg/mL propi-
dium iodine in 200 uL of 1x binding buffer (140 mM
NaCl, 2.5 mM CaCl2, and 10mM HEPES) for 15min.
Cells were then analyzed on FACS Calibur Flow
Cytometer.
Mitochondrial membrane potential assays
WM793TR LacZ and CADM1 cells were seeded in 6-
well plates, or ultra-low adherent 6-well plates. The
next day, cells were dosed with doxycycline at 100 ng/
mL to induce transgene expression. Cells were incu-
bated for ~20 h, collected, and stained for 40 min at 37 °
C with Mitotracker Red CMXRos (Invitrogen #M7512)
at 100 nM and Mitotracker GreenFM (Invitrogen
#M7514) at 100 nM. Cells were then washed 2x with
PBS and stained with Zombie Aqua (Biolegend
#423101) (0.2 uL per 100 uL PBS) for 10 min. Samples
were then washed and resuspended in FACS buffer
(1% FBS and 0.05% sodium azide in ×1 PBS) for ana-
lysis on BD Celesta. Experiments were independently
performed 3 times and data was analyzed with FlowJo
software. Debris was gated out via FSC/SSC and then
only Mitotracker GreenFM positive cells were used to
assay CMXRos.
Skin reconstructs
Skin reconstructs were created similar to57. 1205LuTR
LacZ and CADM1 cells (1 × 105) were added to the epi-
dermal layer for analysis. Skin reconstruct media is
changed every two days. After seven days of incubation,
skins were dosed with DMSO or doxycycline at 100 ng/
mL and incubated an additional 7 days. Skins were ﬁxed
in 4% buffered formalin and parafﬁn embedding.
Tissue microarray analysis
Tissue microarray (US Biomax #ME1004d) was stained
with anti-CADM1 antibody (Abcam #ab138697). The
percent positivity of tumor tissue was scored by a blinded
pathologist. The scoring of non-pigmented lesions was
then categorized into cohorts of benign skin nevi, in situ
melanoma, and metastatic melanoma. Statistics were
analyzed with the independent samples Kruskal-Wallis
test using Bonferroni corrections for multiple compar-
isons in Graphpad Prism.
Soft agar colony formation
Brieﬂy, 1 mL of 0.8% bacto-agar in WM media used to
coat the bottom of a 12-well plate. After solidifying, 2
mL of 0.5% bacto-agar in WM media with 4000 cells/mL
was overlaid. Finally, 1 mL of WM media with doxycy-
cline (100 ng/mL ﬁnal concentration) was added. Med-
ium was routinely changed, and images were taken after
four weeks of incubation with a Nikon Eclipse Ti
inverted microscope (Nikon, Melville, NY) with NIS-
Elements AR 3.00 software (Nikon) equipped with 4x
objective. Three random ﬁelds per well were docu-
mented, WM793TR LacZ cells and CADM1 cells were
seeded in triplicate for each experiment. Experiment
was repeated four times. Images were quantiﬁed by
ImageJ software.
siRNA transfection
Cells were transfected for 4 h with siRNAs (Dharmacon)
at a ﬁnal concentration of 25 nM using oligofectamine
(Invitrogen). Cells were harvested for lysates 72 h after
transfections. TWIST1 siRNA sequences: #2 CUGCAG
ACGCAGCGGGUCA, #5 GGAGUCCGCAGUCUUAC
GA, #7 UGAGCAACAGCGAGGAAGA.
Quantitative reverse transcriptase-PCR
RNA was extracted using PerfectPure RNA Cultured
Cell Kit (5Prime) as per the manufacturer's instructions.
RNA was then converted to cDNA using iScript cDNA
Sythesis Kit (Bio-Rad). Analysis was done by utilizing iQ
SYBR Green Supermix (Bio-Rad) in quantitative reverse
transcriptase qRT-PCR. Relative fold changes in mRNA
levels were calculated after normalization to β-actin using
the comparative Ct method
58. qRT-PCR primers: CADM1
F: TTTGAAGGACAGCAGGTTTCA, CADM1 R: AGGA
CTGTGATGGTGGTGTAACT, TWIST1 F: AGTCTT
ACGAGGAGCTGCAGACG, TWIST1 R: AGGAAGTC
GATGTACCTGGCCG
Inhibitors
Z-VAD FMK, PLX4720, trametinib, dabrafenib, talazo-
parib, and olaparib were purchased from Selleck (Hous-
ton, TX).
Western blotting
Blotting was performed as previously described59.
Antibodies used were: TWIST1 (#sc-81417), ERK2 (#sc-
1647), and BRAF (#sc-166) from Santa Cruz Biotechnol-
ogy (Dallas, TX), CADM1 antibodies #ab3910 and
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#ab138697 were purchased from Abcam (Cambridge,
MA). pERK1/2 (#9101), Cleaved Caspase 3 (#9661), ErbB3
(#4754), and GAPDH (#2118) was purchased from Cell
Signaling (Danvers, MA). Actin (#A2066) was from Sigma
(St. Louis, MO) and Poly(ADP-ribose) (PAR) (#ALX-804-
220-R100) was purchased from Enzo (Farmingdale, NY).
Anti-V5 epitope was purchased from Invitrogen (Carls-
bad, CA). Chemiluminence was visualized with VersaDoc
MultiImager and quantiﬁed using Quantity-One software
(Bio-Rad, Hercules, CA).
Microscopy
7 × 104 cells were cultured on glass coverslips overnight,
and then washed with PBS, and ﬁxed in ice cold methanol.
Fixed cells were then stained overnight at 4 °C with anti
CADM1 (Abcam #3910) at 1:200. Primary antibody was
washed, then stained with an anti-rabbit GFP conjugated
secondary antibody (Molecular Probes, Grand Island, NY)
at 1:2000. Secondary antibody was then washed and cells
were counter stained with TRITC conjugated phalloidin
(Sigma, St. Louis, MO) and mounted with Prolong Gold
Antifade reagent with DAPI (Molecular Probes, Grand
Island, NY). Slides were imaged on Nikon Eclipse Ti
inverted microscope (Nikon, Melville, NY) with NIS-
Elements AR 3.00 software (Nikon) utilizing a 40x
objective.
Invasion and migration assay
Cells were treated with doxycycline at 100 ng/mL to
induce expression of LacZ, CADM1, or shRNA constructs.
After 24 h, cells were serum starved for an additional 24 h.
For invasion assays, 8.0 μm cell culture inserts from BD
Biosciences (San Jose, CA) were coated with 0.75mg/ml
Matrigel; migrations assays used non-coated 8.0 μM boyden
chambers. Serum starved cells (3.75 × 104) were seeded in
the chamber with serum-free media supplemented with
doxycycline. Cells were left to migrate or invade though
Matrigel towards serum containing media attractant for a
total of 24 h. Inserts were then removed, and ﬁxed with
buffered formalin. Cells were then stained with crystal
violet, and membrane inserts were mounted for micro-
scopic analysis. Images were taken using 10x objective lens
on the Nikon Eclipse Ti inverted microscope (Nikon,
Melville, NY). A total of 3 random ﬁelds were analyzed for
each membrane. Quantiﬁcation was performed utilizing
NIS Elements (Nikon). The experiment was carried out
three independent times in duplicate (for a total of 18 cell
counts per experimental condition).
Spheroid outgrowth assay
96-well plates were coated with 50 uL of 1.5% agarose in
PBS. Cells (5 × 104) were then seeded and allowed to form
spheroids for 5–7 days. Spheroids were collected with a
transfer pipette and resuspended in collagen mixture (per
mL: 100 uL 10x reconstruct buffer (NaOH 0.05M,
NaHCO3 2.2%, HEPES 200mM), 100 uL HAM-F12 10x
(Gibco #21700–26), 750 uL Collagen I Rat tail (Corning
#354236) and 50 uL FBS). Collagen was left to solidify for
~two hours then WM media with doxycycline (ﬁnal
concentration of 100 ng/mL) was overlaid. After 48 h
incubation, WM media was aspirated, and cells were then
labeled by adding 300 uL of PBS containing 150 nM
Calcien AM. Spheroids were then imaged by immuno-
ﬂuorescent microscopy using 10x objective. Invasive
index was calculated by the area ratios of the sprouting
cells per the area of the spheroid as determined by ImageJ.
Each experimental group consisted of at least n= 40
across three different experiments.
TCGA analysis
Cox proportional hazards model was used to model
the OS and PFS with proportional hazards assumption
validated. The following variables were considered as
predictors of OS in the multivariate model: age_at_i-
nitial_pathologic_diagnosis, gender, tumor_weight,
breslow_depth_value, history_of_neoadjuvant_treat-
ment, sample_type, melanoma_ulceration_indicator,
postoperative_rx_tx, radiation_therapy, BRAF V600
mutation, and NRAS Q61 mutation, as well as inter-
actions between CADM1 levels and sample_type,
BRAF V600 mutation, and NRAS Q61 mutation. In
addition, the multivariate Cox model included covari-
ates adjusting for TNM-staging. The variables patho-
logic_T, pathologic_N, and pathologic_M were
grouped into categories 0–4 according to the numer-
ical status with resulting covariates T-stage, N-stage,
and M-stage. Due to a small number of patients with
Stage M1, the M-stage was not used in multivariate
Cox models. Also, 23 patients with T-Stage= 0 and
melanoma ulceration indicator missing were excluded
from the multivariate analysis of OS. The ﬁnal Cox
model for OS was obtained by backward elimination of
non-signiﬁcant predictors of OS. Since the PFS data
available for analysis includes only 17 events in 114
patients, each stage variable (T-stage, N-stage) and
other covariate was considered with CADM1 in sepa-
rate Cox models. The data were analyzed in R (The
R Foundation for Statistical Computing http://www.R-
project.org).
Scratch wound assay
1205LuTR LacZ or CADM1 cells (3.75 × 105) were
seeded in 6-well dishes. The next day cells were treated
with 100 ng/mL doxycycline to induce transgene expres-
sion. Cells were then grown to conﬂuence (~4 days), and
which point a 2 mL pipette tip was used to scratch a
“wound” in the conﬂuent monolayer. Images were taken
with 4x objective for T= 0. 4× images also taken at
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T= 48 h. Length of each wound was determined with NIS
Elements (Nikon) at 5 different points along the scratch.
Data is represented as fold wound opening from T= 0.
Experiments were performed three times.
Acknowledgements
We are grateful to Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA) for
the WM melanoma cell lines and Dr. Mauricio Reginato (Drexel University,
Philadelphia PA) for thoughtful scientiﬁc input.
Author details
1Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
19107, USA. 2Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA
19107, USA. 3Department of Pharmacology and Physiology at Drexel University
College of Medicine, Philadelphia, PA 19102, USA. 4Departments of Pathology,
Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, PA
19107, USA. 5Division of Biostatistics in Pharmacology and Experimental
Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
Funding
This work was supported by the National Cancer Center and National Institutes
of Health (NIH) (K99/R00 CA207855) to E.J. Hartsough, and (R01 CA182635, R01
CA196278) to A.E. Aplin, and the Dr. Miriam and Sheldon G. Adelson Medical
Research Foundation to A.E. Aplin. D. A. Erkes is supported by an American
Cancer Society—CEO’s Against Cancer—PA Chapter Postdoctoral Fellowship
(PF-18-096-01-LIB). The Sidney Kimmel Cancer Center Flow Cytometry,
Translational Pathology and Meta-Omics core facilities are supported by NIH/
National Cancer Institute Support Grant (P30 CA056036).
Conﬂict of interest
A.E. Aplin reports receiving a commercial research grant from Pﬁzer Inc. (2013-
2017), has ownership interest in patent number 9880150 and has consulted for
SpringWorks Therapeutics and Fortress Biotech within the last 3 years. No
potential conﬂicts of interest were disclosed by the other authors.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41419-019-1515-3).
Received: 27 November 2018 Revised: 5 March 2019 Accepted: 7 March
2019
References
1. Friedl, P. & Wolf, K. Tumour-cell invasion and migration: diversity and escape
mechanisms. Nat. Rev. Cancer 3, 362–374 (2003).
2. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-
mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).
3. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential
role in tumor metastasis. Cell 117, 927–939 (2004).
4. Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal
regulation of epithelial-mesenchymal transition is essential for squamous cell
carcinoma metastasis. Cancer Cell. 22, 725–736 (2012).
5. Pearlman, R. L., Montes de Oca, M. K., Pal, H. C. & Afaq, F. Potential therapeutic
targets of epithelial-mesenchymal transition in melanoma. Cancer Lett. 391,
125–140 (2017).
6. Li, F. Z., Dhillon, A. S., Anderson, R. L., McArthur, G. & Ferrao, P. T. Phenotype
switching in melanoma: implications for progression and therapy. Front.
Oncol. 5, 31 (2015).
7. Weiss, M. B. et al. TWIST1 is an ERK1/2 effector that promotes invasion and
regulates MMP-1 expression in human melanoma cells. Cancer Res. 72,
6382–6392 (2012).
8. Knights, A. J., Funnell, A. P., Crossley, M. & Pearson, R. C. Holding tight: cell
junctions and cancer spread. Trends Cancer Res 8, 61–69 (2012).
9. Takai, Y., Irie, K., Shimizu, K., Sakisaka, T. & Ikeda, W. Nectins and nectin-like
molecules: roles in cell adhesion, migration, and polarization. Cancer Sci. 94,
655–667 (2003).
10. Biederer, T. Bioinformatic characterization of the SynCAM family of
immunoglobulin-like domain-containing adhesion molecules. Genomics 87,
139–150 (2006).
11. Maurel, P. et al. Nectin-like proteins mediate axon Schwann cell interactions
along the internode and are essential for myelination. J. Cell Biol. 178, 861–874
(2007).
12. Niederkoﬂer, V., Baeriswyl, T., Ott, R. & Stoeckli, E. T. Nectin-like molecules/
SynCAMs are required for post-crossing commissural axon guidance. Devel-
opment 137, 427–435 (2010).
13. Robbins, E. M. et al. SynCAM 1 adhesion dynamically regulates synapse
number and impacts plasticity and learning. Neuron 68, 894–906 (2010).
14. Yamada, D. et al. Disruption of spermatogenic cell adhesion and male infer-
tility in mice lacking TSLC1/IGSF4, an immunoglobulin superfamily cell
adhesion molecule. Mol. Cell. Biol. 26, 3610–3624 (2006).
15. Raveh, S., Gavert, N., Spiegel, I. & Ben-Ze'ev, A. The cell adhesion nectin-like
molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of
colon cancer cells. J. Cell Biochem. 108, 326–336 (2009).
16. Chang, G. et al. Hypoexpression and epigenetic regulation of candidate tumor
suppressor gene CADM-2 in human prostate cancer. Clin. Cancer Res. 16,
5390–5401 (2010).
17. Berger, M. F. et al. The genomic complexity of primary human prostate cancer.
Nature 470, 214–220 (2011).
18. Kuramochi, M. et al. TSLC1 is a tumor-suppressor gene in human non-small-
cell lung cancer. Nat. Genet. 27, 427–430 (2001).
19. Chockley, P. J. et al. Epithelial-mesenchymal transition leads to NK cell-
mediated metastasis-speciﬁc immunosurveillance in lung cancer. J. Clin. Invest.
128, 1384–1396 (2018).
20. Lung, H. L. et al. TSLC1 is a tumor suppressor gene associated with metastasis
in nasopharyngeal carcinoma. Cancer Res. 66, 9385–9392 (2006).
21. Murakami, Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human
oncogenesis. Cancer Sci. 96, 543–552 (2005).
22. Takai, Y., Miyoshi, J., Ikeda, W. & Ogita, H. Nectins and nectin-like molecules:
roles in contact inhibition of cell movement and proliferation. Nat. Rev. Mol.
Cell Biol. 9, 603–615 (2008).
23. Sun, C. X., Robb, V. A. & Gutmann, D. H. Protein 4.1 tumor suppressors: getting
a FERM grip on growth regulation. J. Cell. Sci. 115(Pt 21), 3991–4000 (2002).
24. Shingai, T. et al. Implications of nectin-like molecule-2/IGSF4/RA175/SgIGSF/
TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization
in epithelial cells. J. Biol. Chem. 278, 35421–35427 (2003).
25. Fukuhara, H. et al. Association of a lung tumor suppressor TSLC1 with MPP3, a
human homologue of Drosophila tumor suppressor Dlg. Oncogene 22,
6160–6165 (2003).
26. Vesuna, F., van Diest, P., Chen, J. H. & Raman, V. Twist is a transcriptional
repressor of E-cadherin gene expression in breast cancer. Biochem. Biophys.
Res. Commun. 367, 235–241 (2008).
27. Vesuna, F. et al. Twist contributes to hormone resistance in breast cancer by
downregulating estrogen receptor-alpha. Oncogene 31, 3223–3234 (2012).
28. Goodnough, L. H. et al. Twist1 mediates repression of chondrogenesis by
beta-catenin to promote cranial bone progenitor speciﬁcation. Development
139, 4428–4438 (2012).
29. Castanon, I. & Baylies, M. K. A Twist in fate: evolutionary comparison of Twist
structure and function. Gene 287, 11–22 (2002).
30. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with
potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 105, 3041–3046 (2008).
31. Basile, K. J. et al. In vivo MAPK reporting reveals the heterogeneity in tumoral
selection of resistance to RAF inhibitors. Cancer Res. 73, 7101–7110 (2013).
32. Bennett, D. C., Cooper, P. J. & Hart, I. R. A line of non-tumorigenic mouse
melanocytes, syngeneic with the B16 melanoma and requiring a tumour
promoter for growth. Int. J. Cancer 39, 414–418 (1987).
33. Weiss, M. B., Abel, E. V., Dadpey, N. & Aplin, A. E. FOXD3 modulates migration
through direct transcriptional repression of TWIST1 in melanoma. Mol. Cancer
Res. 12, 1314–1323 (2014).
34. Yang, W. H. et al. RAC1 activation mediates Twist1-induced cancer cell
migration. Nat. Cell Biol. 14, 366–374 (2012).
35. Ito, T. et al. Involvement of TSLC1 in progression of esophageal squamous cell
carcinoma. Cancer Res. 63, 6320–6326 (2003).
Hartsough et al. Cell Death and Disease          (2019) 10:281 Page 14 of 15
Ofﬁcial journal of the Cell Death Differentiation Association
36. Yageta, M. et al. Direct association of TSLC1 and DAL-1, two distinct tumor
suppressor proteins in lung cancer. Cancer Res. 62, 5129–5133 (2002).
37. Masuda, M. et al. Tumor suppressor in lung cancer (TSLC)1 suppresses epi-
thelial cell scattering and tubulogenesis. J. Biol. Chem. 280, 42164–42171
(2005).
38. Sakurai-Yageta, M., Maruyama, T., Suzuki, T., Ichikawa, K. & Murakami, Y.
Dynamic regulation of a cell adhesion protein complex including CADM1 by
combinatorial analysis of FRAP with exponential curve-ﬁtting. PLoS. One. 10,
e0116637 (2015).
39. Schafer, Z. T. et al. Antioxidant and oncogene rescue of metabolic defects
caused by loss of matrix attachment. Nature 461, 109–113 (2009).
40. Mimae, T. et al. Increased ectodomain shedding of lung epithelial cell adhe-
sion molecule 1 as a cause of increased alveolar cell apoptosis in emphysema.
Thorax 69, 223–231 (2014).
41. Bai, P., Nagy, L., Fodor, T., Liaudet, L. & Pacher, P. Poly(ADP-ribose) polymerases
as modulators of mitochondrial activity. Trends Endocrinol. Metab. 26, 75–83
(2015).
42. Cregan, S. P., Dawson, V. L. & Slack, R. S. Role of AIF in caspase-dependent and
caspase-independent cell death. Oncogene 23, 2785–2796 (2004).
43. Ha, H. C. & Snyder, S. H. Poly(ADP-ribose) polymerase is a mediator of
necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. USA 96,
13978–13982 (1999).
44. Tania, M., Khan, M. A. & Fu, J. Epithelial to mesenchymal transition inducing
transcription factors and metastatic cancer. Tumour Biol. 35, 7335–7342 (2014).
45. Ansieau, S. et al. Induction of EMT by twist proteins as a collateral effect of
tumor-promoting inactivation of premature senescence. Cancer Cell. 14,
79–89 (2008).
46. Hoek, K. et al. Expression proﬁling reveals novel pathways in the transfor-
mation of melanocytes to melanomas. Cancer Res. 64, 5270–5282 (2004).
47. Wang, J. X., Fukunaga-Kalabis, M. & Herlyn, M. Crosstalk in skin: melanocytes,
keratinocytes, stem cells, and melanoma. J. Cell. Commun. Signal. 10, 191–196
(2016).
48. Zhang, J. et al. A novel oncolytic adenovirus targeting Wnt signaling effectively
inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy
in HCC models. Biochem. Biophys. Res. Commun. 491, 469–477 (2017).
49. Giangreco, A., Jensen, K. B., Takai, Y., Miyoshi, J. & Watt, F. M. Necl2 regulates
epidermal adhesion and wound repair. Development 136, 3505–3514 (2009).
50. Klinac, D. et al. Monitoring changes in circulating tumour cells as a prognostic
indicator of overall survival and treatment response in patients with metastatic
melanoma. Bmc. Cancer 14, 423 (2014).
51. Amaria, R. N. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib
versus standard of care in patients with high-risk, surgically resectable mela-
noma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 19,
181–193 (2018).
52. Conrad, M., Angeli, J. P., Vandenabeele, P. & Stockwell, B. R. Regulated necrosis:
disease relevance and therapeutic opportunities. Nat. Rev. Drug. Discov. 15,
348–366 (2016).
53. David, K. K., Andrabi, S. A., Dawson, T. M. & Dawson, V. L. Parthanatos, a
messenger of death. Front Biosci. 14, 1116–1128 (2009).
54. Hong, A. et al. Exploiting Drug Addiction Mechanisms to Select against
MAPKi-Resistant Melanoma. Cancer Discov. 8, 74–93 (2018).
55. Middleton, M. R. et al. Randomized phase II study evaluating veliparib (ABT-
888) with temozolomide in patients with metastatic melanoma. Ann. Oncol.
26, 2173–2179 (2015).
56. Sandhu, S. K. et al. The poly(ADP-ribose) polymerase inhibitor niraparib
(MK4827) in BRCA mutation carriers and patients with sporadic cancer: a
phase 1 dose-escalation trial. Lancet Oncol. 14, 882–892 (2013).
57. Tiago, M. et al. Fibroblasts protect melanoma cells from the cytotoxic effects of
doxorubicin. Tissue Eng. Part. A. 20, 2412–2421 (2014).
58. Pfafﬂ, M. W. A new mathematical model for relative quantiﬁcation in real-time
RT-PCR. Nucleic Acids Res. 29, e45 (2001).
59. Hu, R. & Aplin, A. E. alphaB-crystallin is mutant B-RAF regulated and contributes
to cyclin D1 turnover in melanocytic cells. Pigment. Cell. Melanoma Res. 23,
201–209 (2010).
Hartsough et al. Cell Death and Disease          (2019) 10:281 Page 15 of 15
Ofﬁcial journal of the Cell Death Differentiation Association
